Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma
이민영, 박찬정, 조영욱, 유은경, 장성수, 서을주, 이정희, 윤덕현, 서철원,
소속 상세정보
이민영 ( Lee Min-Young ) - Kyung Hee University School of Medicine Department of Laboratory Medicine
박찬정 ( Park Chan-Jeoung ) - University of Ulsan College of Medicine Asan Medical Center Department of Laboratory Medicine
조영욱 ( Cho Young-Uk ) - University of Ulsan College of Medicine Asan Medical Center Department of Laboratory Medicine
유은경 ( You Eun-Kyoung ) - Inje University College of Medicine Busan Baik Hospital Department of Laboratory Medicine
장성수 ( Jang Seong-Soo ) - University of Ulsan College of Medicine Asan Medical Center Department of Laboratory Medicine
서을주 ( Seo Eul-Ju ) - University of Ulsan College of Medicine Asan Medical Center Department of Laboratory Medicine
이정희 ( Lee Jung-Hee ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
윤덕현 ( Yoon Dok-Hyun ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
서철원 ( Suh Cheol-Won ) - University of Ulsan College of Medicine Asan Medical Center Department of Oncology
Abstract
Background: Plasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable for therapeutic use of PD-1 blockade in PCM.
Methods: A total of 188 bone marrow (BM) samples from 166 PCM patients and 32 controls were prospectively collected between May 2016 and May 2017. PD-1 expression on BM T cell subsets was measured using flow cytometry.
Results: At diagnosis, the median PD-1 expression on CD4+ T cells was 24.6%, which did not significantly differ from that in controls. After stem cell transplantation, PD-1 expression on CD4+ T cells was higher than that at diagnosis (P <0.001), regardless of residual disease. PD-1 expression on CD4+ T cells in patients with residual disease after chemotherapy was significantly higher than that at diagnosis (P =0.001) and after complete remission following chemotherapy (P =0.044). PD-1 expression on CD8+ T cells was higher in PCM patients with cytogenetic abnormalities, including monosomy 13, 1q gain, complex karyotype, and hypodiploidy.
Conclusions: PD-1 blockade might have therapeutic potential in refractory PCM patients after chemotherapy, especially in those with high- or intermediate-risk cytogenetic abnormalities.
키워드
Plasma cell myeloma; Immune checkpoint programmed cell death protein-1 (PD-1); Flow cytometry; T cell subset
원문 및 링크아웃 정보
등재저널 정보